CFTR Modulator Therapy For Cystic Fibrosis
2020
Introduction Cystic fibrosis (CF) is the most common life-limiting autosomal recessive condition in Caucasians, affecting the respiratory system, digestive tract and all exocrine glands. It is caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The genetic analysis, in addition to diagnosis, serves to create a modern individual CFTR modulator therapy. Aim: The aim of this article is to do a presentation of products for CFTR modulator therapy, which are available worldwide; introduction to their pharmacokinetic and pharmacodynamic properties; evaluation of the effect of their application. Materials: We have conducted a study of medical literature related to the products for CFTR modulator therapy and review of information on the topic. Results: The use of approved CFTR modulator therapy products in patients suitable for their use (specific genotype) results in an improvement in FEV1 values and body mass index and a reduction in the incidence of exacerbations in these patients. Conclusion: CFTR modulator therapy significantly improves the prognosis and quality of life of cystic fibrosis patients as a result of certain mutations in the CFTR gene. Quality care for other patients with other mutations is especially important so that they can benefit from personalized treatment in the future.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI